ConductScience.org, home

Trial · NCT01644643

Outcomes38

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYClinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYClinical Response at End of Treatment (EOT) in mMITT Analysis Set.28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYClinical Response at Follow-up 1 (FU1) in mMITT Analysis SetcIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomizationMicrobiological modified intent to treatParticipantNUMBER
SECONDARYClinical Response at Follow-up 2 (FU2) in mMITT Analysis SetAt FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomizationMicrobiological modified intent to treatParticipantNUMBER
SECONDARYClinical Response at EOT in Extended Microbiologically Evaluable (EME) at EOT Analysis Set.28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.Extended Microbiological Evaluable at EOT analysis set.ParticipantNUMBER
SECONDARYClinical Response at TOC in EME at TOC Analysis Set.6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.Extended Microbiological Evaluable at TOC analysis set.ParticipantNUMBER
SECONDARYClinical Response at FU1 in EME at FU1 Analysis Set.cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomizationExtended Microbiological Evaluable at FU1 analysis set.ParticipantNUMBER
SECONDARYClinical Response at FU2 in EME at FU2 Analysis SetAt FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomizationExtended Microbiological Evaluable at FU2 analysis set.ParticipantNUMBER
SECONDARYClinical Cure at TOC by Baseline Gram-negative Pathogen in mMITT Analysis Set6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYClinical Cure at TOC by Baseline Gram-negative Pathogen in EME at TOC Analysis Set6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.Extended microbiologically evaluable at TOCParticipantNUMBER
SECONDARYClinical Cure at TOC by Previously Failed Treatment Class in mMITT Analysis Set6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYClinical Cure at EOT by Previously Failed Treatment Class in EME at EOT Analysis Set28 hours after completion of last infusion of study therapy.Duration of study therapy was 5 to 21 days.Extended microbiologically evaluable at EOTParticipantNUMBER
SECONDARYClinical Cure at TOC by Previously Failed Treatment Class in EME at TOC Analysis Set6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.Extended microbiologically evaluable at TOCParticipantNUMBER
SECONDARYClinical Cure at FU1 by Previously Failed Treatment Class in EME at FU1 Analysis SetcIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomizationExtended microbiologically evaluable at FU1ParticipantNUMBER
SECONDARYClinical Cure at FU2 by Previously Failed Treatment Class in EME at FU2 Analysis SetAt FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomizationExtended microbiologically evaluable at FU2ParticipantNUMBER
SECONDARYPer-patient Microbiological Response at EOT in mMITT Analysis Set28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYPer-patient Microbiological Response at TOC in mMITT Analysis Set6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.Microbiological modified intent to treatParticipantNUMBER
SECONDARYPer-patient Microbiological Response at FU1 in mMITT Analysis SetcUTI: 20-27 calendar days from randomization/cIAI: 27-37 calendar days from randomizationMicrobiological modified intent to treatParticipantNUMBER
SECONDARYPer-patient Microbiological Response at FU2 in mMITT Analysis SetAt FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomizationMicrobiological modified intent to treatParticipantNUMBER
SECONDARYPer-patient Microbiological Response at EOT in EME at EOT Analysis Set28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.Extended microbiologically evaluable at EOTParticipantNUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01644643/outcomes